CHEK2 and ductal breast carcinoma in situ: Petridis et al., studied DCIS patients diagnosed before age 50 and detected CHEK2 pathogenic mutations in 2.4% of 655 DCIS cases, OR for a CHEK2 mutation was 8.0 (95%CI 2.9–22.1) [50].